DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
ADA399996
Title:
Apoptosis Based Gene Therapy of Breast Cancer
Descriptive Note:
Annual summary
Corporate Author:
VIRGINIA COMMONWEALTH UNIV RICHMOND
Report Date:
2001-08-01
Pagination or Media Count:
6.0
Abstract:
This project is an attempt to develop a gene therapy model for the treatment of metastatic breast cancer. Our goal is to develop adenoviral vectors that deliver a cytocidal gene selectively to breast cancer cells. We have employed recombinant molecules of caspase-3, a distal effector protein in the apoptotic cascade. Recombinant caspase-3 molecule, unlike the parent molecule, is constitutively active expression of it in breast cancer cells rapidly induces apoptosis. As expression of caspase-3 in non-malignant cells could be toxic, we are attempting to limit expression to cancer cells by employing breast and tumor specific promoters. We have demonstrated that the promoter of the Hexokinase-Ti gene is tumor specific and the mammoglobin promoter is expressed only in breast cells. In order to tightly control expression to cancer cells we are attempting to employ the CRE I Lox system. One adenovirus would express the CRE gene under the control of the Hexokinase-Il promoter. Another adenovirus would express an inactivated recombinant caspase-3 under control of the mammoglobin promoter. Only the co-infection of these two viruses in cells in which both of these promoters are active, i.e. breast cancer cells, would permit the expression of caspase-3. These viruses are presently being constructed.
Distribution Statement:
APPROVED FOR PUBLIC RELEASE